Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease

Aug 11, 2025
1 min read

CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.

https://vimeo.com/1109180648

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight